4502.T

N/A

Takeda Pharmaceutical Company Limited — PEG Ratio Analysis

—

PEG Ratio

Negative EPS growth — PEG not meaningful when earnings are declining

—

Growth Rate Source

Good Data Quality5-Year EPS CAGR

Current Price

$5118.00

TTM EPS

$119.87

P/E Ratio

42.70

Growth Rate

-12.7%

5-Year EPS CAGR

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Calculated

6/17/2026

9:04:17 AM

PEG Ratio Unavailable

Negative Growth — PEG not meaningful

Peer Comparison

Sample Size

4 peers

Industry Median PEG

0.59

25th Percentile

0.52

75th Percentile

0.70

Symbol	Company	PEG	P/E	Growth	vs 4502.T
8316.T	Sumitomo Mitsui Financial Group, Inc.	0.52	14.1	27.0%	—
8306.T	Mitsubishi UFJ Financial Group, Inc.	0.52	15.0	28.6%	—
4568.T	Daiichi Sankyo Company, Limited	0.66	19.2	29.1%	—
4503.T	Astellas Pharma Inc.	0.70	14.1	20.2%	—

How to Interpret PEG Ratio

PEG < 1.0 — Potentially Undervalued. The stock may be priced below its earnings growth rate, suggesting a potential buying opportunity.

PEG 1.0–2.0 — Fairly Valued. The stock price is roughly in line with its earnings growth. A PEG of 1.0 is often considered "fair value."

PEG > 2.0 — Potentially Overvalued. The stock may be priced above what its earnings growth justifies.

Limitations:PEG ratios are less reliable for financial firms (earnings driven by interest margins), companies with negative/zero earnings growth, and hypergrowth companies (>100% growth) where the ratio may appear misleadingly low. Always use PEG alongside other valuation metrics.